Cost-effectiveness of endoscopic screening followed by surveillance for Barrett's esophagus: a review.
Screening interventions for Barrett's esophagus (BE) are appealing, but there is little supporting evidence. We reviewed health economics studies about BE endoscopic screening followed by, as required, endoscopic surveillance ("screening and surveillance" hereafter) to help inform the design and conduct of future research. Health economics studies about BE screening and surveillance were identified using electronic database searches and personal contact with authors of identified studies. No studies examined general population screening. Five US studies published between 2003 and 2007 examined the cost effectiveness of screening and surveillance (against no intervention) in patients with chronic gastroesophageal reflux disease (GERD). There was no randomized trial evidence to inform model construction. Assumptions about prevalence and transition probabilities between BE histologic subtypes and about surveillance and treatment protocols varied substantially between studies. Parameters such as potential BE diagnosis-related reduction in quality of life or increase in health care use, diagnostic accuracy, and infrastructural costs (for quality assurance) were considered either "optimistically" or not at all. Only 2 studies considered endoscopic treatments. No study considered the recently introduced radiofrequency ablation technique, or the potential for biomarker-based risk stratification of surveillance interval or duration. Current health economics evidence is likely to have provided optimistic cost-effectiveness estimates and is not sufficient to support introduction of endoscopic BE screening programs among GERD patients. The evidence does not adequately incorporate novel (endoscopic) treatments and the potential for (clinical, endoscopic, or biomarker-based) risk stratification of surveillance. Future research should aim to encompass both these factors.
Barbiere
Josephine M
JM
Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom.
Lyratzopoulos
Georgios
G
D001471:Barrett Esophagus / Q000175:diagnosis* / Q000191:economics / Q000209:etiology / Q000628:therapy; D002908:Chronic Disease; D003362:Cost-Benefit Analysis; D018450:Disease Progression; D004945:Esophagoscopy / Q000191:economics*; D019317:Evidence-Based Medicine; D005764:Gastroesophageal Reflux / Q000150:complications / Q000175:diagnosis* / Q000191:economics / Q000628:therapy; D017048:Health Care Costs; D006801:Humans; D008390:Markov Chains; D008403:Mass Screening / Q000191:economics* / Q000379:methods; D018803:Models, Economic; D011237:Predictive Value of Tests; D012107:Research Design; D013997:Time Factors